CN103272068B - Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof - Google Patents
Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof Download PDFInfo
- Publication number
- CN103272068B CN103272068B CN201310186990.8A CN201310186990A CN103272068B CN 103272068 B CN103272068 B CN 103272068B CN 201310186990 A CN201310186990 A CN 201310186990A CN 103272068 B CN103272068 B CN 103272068B
- Authority
- CN
- China
- Prior art keywords
- tilmicosin
- isatidis
- compound preparation
- western medicine
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 96
- 229960000223 tilmicosin Drugs 0.000 title claims abstract description 69
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 60
- 150000001875 compounds Chemical class 0.000 title claims abstract description 40
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 54
- 229960003080 taurine Drugs 0.000 claims abstract description 27
- 239000000463 material Substances 0.000 claims abstract description 15
- 238000011049 filling Methods 0.000 claims abstract description 11
- 239000010231 banlangen Substances 0.000 claims description 42
- 239000009636 Huang Qi Substances 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 28
- 229920002472 Starch Polymers 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 20
- 239000008107 starch Substances 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 208000023504 respiratory system disease Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 239000000273 veterinary drug Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 244000144977 poultry Species 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000018569 Respiratory Tract disease Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003640 drug residue Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960001163 pidotimod Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- -1 tilmicosin compound Chemical class 0.000 description 2
- ZMOUALJOEYJPSZ-BDMZYGHZSA-N (4r,5s,6s,7r,9r,11e,13e,15s,16r)-6-[(2r,3r,4s,5s,6r)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-7-[2-[(3s,5r)-3,5-dimethylpiperidin-1-yl]ethyl]-16-ethyl-4-hydroxy-15-[(2s,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy-5,9,13-trimeth Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)O[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O ZMOUALJOEYJPSZ-BDMZYGHZSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- HCOLPNRPCMFHOH-UHFFFAOYSA-N Prodigiosin Natural products CCCCCC1C=C(C=C/2N=C(C=C2OC)c3ccc[nH]3)N=C1C HCOLPNRPCMFHOH-UHFFFAOYSA-N 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 235000019206 astragalus extract Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000031972 neutrophil apoptotic process Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- TWFGRJUTAULJPZ-USZBIXTISA-N prodigiosin Chemical compound N1=C(C)C(CCCCC)=C\C1=C/C1=NC(C=2[N]C=CC=2)=C[C]1OC TWFGRJUTAULJPZ-USZBIXTISA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a Chinese and western medicine compound preparation containing tilmicosin. The Chinese and western medicine compound preparation containing tilmicosin comprises the following components by mass percent: 2-30% of tilmicosin, 0.5-10% of taurine, 5-30% of milkvetch, 5-30% of isatis root, 5-30% of indigowoad leaf and the balance of officinal filling auxiliary material. The invention also discloses a preparation method of the Chinese and western medicine compound preparation containing tilmicosion. The Chinese and western medicine compound preparation containing tilmicosion has the advantages of stable effect, convenience in application and easiness in preparation when being used for treating respiratory diseases of beasts and birds.
Description
Technical field
The present invention relates to veterinary drug technical field, be specifically related to a kind of Chinese medicine and western medicine compound preparation containing tilmicosin and preparation method thereof, this Chinese medicine and western medicine compound preparation is mainly used in treating livestock and birds respiratory disease.
Background technology
Tilmicosin, it is the special antibiotic of semi-synthetic Macrolide poultry of being succeeded in developing by Elanco Animal Health Care Products Corporation of Britain the eighties in 20th century, all gram positive bacterias and part gram negative bacteria, mycoplasma, spirillum etc. are all had to inhibitory action, to animals such as pig, cattle, sheep, by the microbial infectious disease of sensitivity, particularly livestock and poultry respiratory tract infection has significant curative effect.As the special antibiotic of novel poultry, its research is also deepened continuously.Current research shows, it is can anti-bacteria albumen synthetic, promotes the defense function (collaborative macrophage produces bactericidal action, impels neutrophil apoptosis, and inflammation-inhibiting occurs) of body, may regulate body's immunity as immune mediator.Tilmicosin plays an important role in the swine diseases prevention and control of antagonism reproductive and respiratory syndrome virus, reproductive and respiratory syndrome inapparent infection, can reduce the risk of reproductive and respiratory syndrome outburst, alleviates swinery symptom, improves health conditions, and obviously mitigation symptoms reduces mortality rate.Tilmicosin is applied in the generation raising sow milk water quality that can reduce mastitis in perinatal stage mother, and medicine also can enter milk protection suckling pig simultaneously, reduces the death rate of delivery room piglet.Tilmicosin is applied in wean and child care piglet aspect, can reduce respiratory tract infection, it's the excessive risk phase that respiratory tract disease infects helps to past piglet degree of safety.Tilmicosin also has specially good effect to haemophilus parasuis, and prevention effect is remarkable.But when tilmicosin uses separately, the course for the treatment of is longer, large usage quantity, cost is high, is unfavorable for applying in actual production.
The patent No. is that the Chinese invention patent of ZL 201110066379.2 discloses a kind of tilmicosin compound preparation and its preparation method and application, in this tilmicosin compound preparation, use the not granted synthetic medicine pidotimod that is applied to animal or food animal in veterinary drug, because to pidotimod, there is not correlational study the aspect such as the drug residue in safety and the food animal in animal applications, and limited this compound preparation veterinary drug produce and veterinary clinic in practical application.
The patent No. is that the Chinese invention patent of ZL 201010503385.5 discloses a kind of compound timicosin oral liquid and preparation method thereof,---astragalus polysaccharides, Radix Isatidis extract---monomer component that Banlangen Polysaccharide, the Flos Lonicerae extract---chlorogenic acid that used Chinese medicine astragalus extract in this compound recipe tilmicosin preparation, it is loaded down with trivial details that these Chinese medicine ingredients through extraction are extracted operation voluntarily, particularly chlorogenic acid of market purchasing price height, quality is also difficult to control.And, this compound recipe tilmicosin preparation need to add various cosolvents and antiseptic, easily causes environmental pollution, and its preparation method also bothers, various cosolvents and the antiseptic that need to add need to heat making, and the pharmaceutical solutions transport trouble of making has also increased cost of transportation.
Summary of the invention
The object of the invention is to overcome the defect of above-mentioned prior art, a kind of Chinese medicine and western medicine compound preparation containing tilmicosin is provided, it is used for the treatment of the respiratory tract disease of poultry, efficacy stability, easy to use.
For achieving the above object, the present invention adopts following technical scheme:
Containing a Chinese medicine and western medicine compound preparation for tilmicosin, it is composed of the following components by mass percentage: tilmicosin 2～30%, taurine 0.5～10%, the Radix Astragali 5～30%, Radix Isatidis 5～30%, and Folium Isatidis 5～30%, surplus is medicinal filling adjuvant.
At the Chinese medicine and western medicine compound preparation containing tilmicosin of the present invention, the drug effect of each component is as follows:
Taurine: taurine is a kind of sulfur-containing amino acid, has multiple pharmacologically active.There is strong liver function of gallbladder promoting liver is had to protective effect; Improve immunity of organisms, antipyretic and antiinflammatory action; There is blood pressure lowering, hypoglycemic activity, anticoagulant and thrombosis; There is heart tonifying and antiarrhythmic effect.Taurine has the cell of enhancing antioxidation, free radical resisting damage and antiviral ability; with the Compound Phase such as vitamin E and vitamin C seemingly; there is the effect of Scavenger of ROS free radical, jointly form the system of defense of life, prevent the injury of toxin to cell and tissue.Taurine is one of free amino acid the abundantest in lymphocyte and granulocyte, can promote lymphocyte proliferation, and it not only can improve specificity and the non-specific immunity of animal, and is a kind of good immunological adjuvant.
The Radix Astragali: the Radix Astragali is important QI invigorating Chinese medicine, its sweet in the mouth, slightly warm in nature, a large amount of experimentatioies show: have enhancing function of immune system, the effects such as anti-inflammatory, antiviral, antitumor, antioxidation, slow down aging, blood sugar lowering, and the immunologic hypofunction animal that intact animal and lotus tumor medicine etc. are caused, all can effectively improve cellular immunization and humoral immune function.
Folium Isatidis: Folium Isatidis clearing away heat and cooling blood, removing toxic substances speckle removing.There is broad-spectrum antibacterial action and antivirus action, there is antiinflammatory, refrigeration function, immunomodulating and antitumor action.
Radix Isatidis: Radix Isatidis has effect of heat-clearing and toxic substances removing, removing heat from blood sore-throat relieving, is usually used in treating epidemic febrile disease etc., is one of traditional anti virus herb.There is antiviral, antibacterial, anti-endotoxin effect and there is immune enhancing function.
Chinese medicine Western medicine of the present invention combines, Radix Astragali invigorating the spleen and replenishing QI spleen invigorating, qi-supplementing, blood-engendering in prescription, Radix Isatidis, the equal prodigiosin heat-clearing and toxic substances removing of Folium Isatidis, Radix Isatidis focuses on removing heat from blood sore-throat relieving, clearing away lung-heat, flat cough with asthma, Folium Isatidis is partial to blood cooling and ecchymoses removing, three taste Chinese medicines share there is replenishing QI to invigorate the spleen hemopoietic, effect of heat-clearing and toxic substances removing, clearing lung, relieving asthma, cooling blood for hemostasis detumescence; Taurine has heart tonifying hepatic cholagogic, enhancing immunity, antipyretic and anti-inflammatory effect; Antibiotic tilmicosin has antibiosis and antiviral functions.The present invention by thering is strengthening vital QI to eliminate pathogenic factors, keep fit to consolidate the effect a permanent cure Chinese medicine of effect and rapid-action taurine, tilmicosin and share, can eliminate the slow weakness of Chinese medicine onset, Chinese and Western is combined with can rapid-actionly keep fit again body and consolidate and strengthen self premunition, improve curative effect of medication, reduced the risk that medicine drug residue in food animal etc. brings; Meanwhile, because having added the Radix Astragali and Radix Isatidis, the delicate fragrance that both are intrinsic and sweet taste, without deliberately adding sweeting agent or correctives, saved production cost and production process again; Moreover each medicine is the common drug in veterinary drug approval aborning, it is convenient to buy, and preparation is simple, veterinary drug produce with clinical practice in easily implement.
As preferred version of the present invention, the Chinese medicine and western medicine compound preparation containing tilmicosin of the present invention, it is composed of the following components by mass percentage: tilmicosin 10～20%; taurine 3～6%, the Radix Astragali 10～20%, Radix Isatidis 10～20%; Folium Isatidis 10～20%, surplus is medicinal filling adjuvant.
As the preferred scheme of the present invention, the Chinese medicine and western medicine compound preparation containing tilmicosin of the present invention, it is composed of the following components by mass percentage: tilmicosin 20%, taurine 6%, the Radix Astragali 20%, Radix Isatidis 20%, Folium Isatidis 20%, medicinal filling adjuvant 14%.
As preferred version of the present invention, the described Radix Astragali, Radix Isatidis, Folium Isatidis are all crushed to superfine powder.Chinese medicine ingredients is crushed to superfine powder and is more conducive to the abundant absorption of animal to Chinese medicine, and then reaches the consumption of minimizing antibiotic tilmicosin and shortened the drug use course for the treatment of and reduced dosage, has improved curative effect of medication.
As more preferably scheme of the present invention, the mean diameter of the described Radix Astragali, Radix Isatidis, Folium Isatidis is all more than 300 orders.
Described in the present invention's formula, medicinal filling adjuvant is starch.
The preparation method that another object of the present invention is to provide the above-mentioned Chinese medicine and western medicine compound preparation containing tilmicosin, it comprises the following steps:
Get by mass percentage the Radix Astragali 5～30%, Radix Isatidis 5～30% is mixed, more progressively add tilmicosin 2～30%, the medicinal filling auxiliary materials and mixing of taurine 0.5～10%, Folium Isatidis 5～30% and surplus.
Preferably, the described Radix Astragali, Radix Isatidis, Folium Isatidis mix after being all first crushed to superfine powder again.
Preferably, the described Radix Astragali, Radix Isatidis, Folium Isatidis to be crushed to respectively mean diameter be more than 300 orders.
Compared with prior art, beneficial effect of the present invention is:
1, the present invention adopts and has strengthening vital QI to eliminate pathogenic factors, keeps fit to consolidate the Chinese medicine of effect of effecting a permanent cure; share with rapid-action taurine, tilmicosin; can eliminate the slow weakness of Chinese medicine onset; Chinese and Western is combined with the rapid-action body of keeping fit again; strengthen premunition, the respiratory tract disease that is used for the treatment of poultry has efficacy stability, advantage easy to use.
2, Chinese medicine of the present invention uses the abundant absorption of the more favourable Chinese medicine of superfine powder technology, and then reach the consumption of minimizing antibiotic tilmicosin and shortened the drug use course for the treatment of and reduced dosage, improve curative effect of medication, reduced the risk that medicine drug residue in food animal etc. brings; Meanwhile, because having added Radix Astragali superfine powder and Radix Isatidis superfine powder, the delicate fragrance that both are intrinsic and sweet taste, without deliberately adding sweeting agent or correctives, saved production cost and production process again; Moreover each medicine is the common drug in veterinary drug approval aborning, it is convenient to buy, and preparation is simple, veterinary drug produce with clinical practice in easily implement.
Detailed description of the invention
Below by specific embodiment, a kind of Chinese medicine and western medicine compound preparation containing tilmicosin of the present invention is described in further detail.
Embodiment 1
Containing a Chinese medicine and western medicine compound preparation for tilmicosin, percent meter is composed of the following components by weight for it: tilmicosin 20%, taurine 6%, the Radix Astragali 20%, Folium Isatidis 20%, Radix Isatidis 20%, starch 14%.
The preparation method of the above-mentioned Chinese medicine and western medicine compound preparation containing tilmicosin is as follows:
1) taurine and starch are carried out to premixing, obtain premixing material;
2) step 1) gained premixing material is always mixed with tilmicosin, Radix Astragali superfine powder, Folium Isatidis superfine powder, Radix Isatidis superfine powder, remaining starch, to obtain final product.
Embodiment 2
The present embodiment is to be further improved on the basis of embodiment 1, and difference is: the described Radix Astragali, Radix Isatidis, Folium Isatidis are all crushed to superfine powder, and the mean diameter of the described Radix Astragali, Radix Isatidis, Folium Isatidis is all more than 300 orders.
Preparation method:
1) Radix Astragali, Radix Isatidis, Folium Isatidis are pulverized with Ultra-Micro Grinding Equipment respectively, make more than their average footpath reach 300 orders;
2)) taurine and starch are carried out to premixing, obtain premixing material;
3) step 2) gained premixing material always mixes with tilmicosin, Radix Astragali superfine powder, Folium Isatidis superfine powder, Radix Isatidis superfine powder, remaining starch, to obtain final product.
Embodiment 3
Containing a Chinese medicine and western medicine compound preparation for tilmicosin, percent meter is composed of the following components by weight for it:
Tilmicosin 20%, taurine 5%, the Radix Astragali 30%, Radix Isatidis 30%, Folium Isatidis 10%, starch 5%.
The preparation method of the above-mentioned Chinese medicine and western medicine compound preparation containing tilmicosin is as follows:
1) Radix Astragali, Radix Isatidis, Folium Isatidis are pulverized with Ultra-Micro Grinding Equipment respectively, make more than their average footpath reach 300 orders;
2)) taurine and starch are carried out to premixing, obtain premixing material;
3) step 2) gained premixing material always mixes with tilmicosin, Radix Astragali superfine powder, Folium Isatidis superfine powder, Radix Isatidis superfine powder, remaining starch, to obtain final product.
Embodiment 4
Containing a Chinese medicine and western medicine compound preparation for tilmicosin, percent meter is composed of the following components by weight for it:
Tilmicosin 10%, taurine 3%, the Radix Astragali 10%, Radix Isatidis 10%, Folium Isatidis 30%, starch 37%.
The preparation method of the above-mentioned Chinese medicine and western medicine compound preparation containing tilmicosin is as follows:
1) Radix Astragali, Radix Isatidis, Folium Isatidis are pulverized with Ultra-Micro Grinding Equipment respectively, make more than their average footpath reach 300 orders;
2)) taurine and starch are carried out to premixing, obtain premixing material;
3) step 2) gained premixing material always mixes with tilmicosin, Radix Astragali superfine powder, Folium Isatidis superfine powder, Radix Isatidis superfine powder, remaining starch, to obtain final product.
Embodiment 5
Containing a Chinese medicine and western medicine compound preparation for tilmicosin, percent meter is composed of the following components by weight for it:
Tilmicosin 5%, taurine 0.5%, the Radix Astragali 5%, Radix Isatidis 30%, Folium Isatidis 5%, starch 54.5%.
The preparation method of the above-mentioned Chinese medicine and western medicine compound preparation containing tilmicosin is as follows:
1) Radix Astragali, Radix Isatidis, Folium Isatidis are pulverized with Ultra-Micro Grinding Equipment respectively, make more than their average footpath reach 300 orders;
2)) taurine and starch are carried out to premixing, obtain premixing material;
3) step 2) gained premixing material always mixes with tilmicosin, Radix Astragali superfine powder, Folium Isatidis superfine powder, Radix Isatidis superfine powder, remaining starch, to obtain final product.
Embodiment 6
Containing a Chinese medicine and western medicine compound preparation for tilmicosin, percent meter is composed of the following components by weight for it:
Tilmicosin 2%, taurine 10%, the Radix Astragali 20%, Radix Isatidis 5%, Folium Isatidis 15%, starch 48%.
The preparation method of the above-mentioned Chinese medicine and western medicine compound preparation containing tilmicosin is as follows:
1) Radix Astragali, Radix Isatidis, Folium Isatidis are pulverized with Ultra-Micro Grinding Equipment respectively, make more than their average footpath reach 300 orders;
2)) taurine and starch are carried out to premixing, obtain premixing material;
3) step 2) gained premixing material always mixes with tilmicosin, Radix Astragali superfine powder, Folium Isatidis superfine powder, Radix Isatidis superfine powder, remaining starch, to obtain final product.
Embodiment 7 clinical effectiveness experiments
1, experimental technique: choose that certain large-scale pig farm is basic identical from numerous autotrophy, feeding and management condition, 100 of the growing and fattening pigs that are diagnosed as respiratory tract disease, be divided at random 2 groups, i.e. experimental group, matched group, 50 every group.The Chinese medicine and western medicine compound preparation containing tilmicosin that experimental group is prepared by the mixed 1000g embodiment 2 of feedstuff per ton is fed; Matched group, feeds by the mixed common pre-mixing agent of 1000g (20% tilmicosin pre-mixing agent, adjuvant is starch) of feedstuff per ton, and two groups of feedings and managements are identical.
2, curative effect judgement:
Cure: the symptom after 2～3 times of offer medicine disappears completely, cough disappears completely, and appetite, the normal person of body temperature are healing.
Effective: offer medicine after 4～5 times, spirit, appetite take a turn for the better, and symptom alleviates, and cough obviously alleviates as effectively.Inefficiency: in medication,, after death or medication 6～7 times, symptom does not alleviate or continues to worsen for invalid, according to
This calculates the rate of failing to respond to any medical treatment of every group.
3, experimental result
Show through clinical observation on the therapeutic effect statistics: the cure rate of experimental group is 84.0% (42/50), effective percentage is 92.0%(46/50), inefficiency 8.0% (4/50), matched group be respectively 72.0%(36/50), 82%(41/50), 18%(9/50).
4, experiment conclusion
The effective percentage of experimental group is higher by 10.0% than matched group, and difference is (p < 0.01) extremely significantly, and tilmicosin soluble powder of the present invention is embodying good clinical effectiveness aspect treatment porcine respiratory disease as can be seen here.
Above-mentioned embodiment is only the preferred embodiment of the present invention; can not limit the scope of protection of the invention with this, the variation of any unsubstantiality that those skilled in the art does on basis of the present invention and replacement all belong to the present invention's scope required for protection.
Claims (9)
1. the Chinese medicine and western medicine compound preparation containing tilmicosin; it is characterized in that composed of the following components by mass percentage: tilmicosin 2～30%, taurine 0.5～10%, the Radix Astragali 5～30%, Radix Isatidis 5～30%; Folium Isatidis 5～30%, surplus is medicinal filling adjuvant.
2. the Chinese medicine and western medicine compound preparation containing tilmicosin as claimed in claim 1, is characterized in that composed of the following components by mass percentage: tilmicosin 10～20%, taurine 3～6%; the Radix Astragali 10～20%; Radix Isatidis 10～20%, Folium Isatidis 10～20%, surplus is medicinal filling adjuvant.
3. the Chinese medicine and western medicine compound preparation containing tilmicosin as claimed in claim 1, composed of the following components by mass percentage: tilmicosin 20%, taurine 6%, the Radix Astragali 20%, Radix Isatidis 20%, Folium Isatidis 20%, medicinal filling adjuvant 14%.
4. the Chinese medicine and western medicine compound preparation containing tilmicosin as described in claims 1 to 3 any one, is characterized in that: the described Radix Astragali, Radix Isatidis, Folium Isatidis are all crushed to superfine powder.
5. the Chinese medicine and western medicine compound preparation containing tilmicosin as claimed in claim 4, is characterized in that: the mean diameter of the described Radix Astragali, Radix Isatidis, Folium Isatidis is all more than 300 orders.
6. the Chinese medicine and western medicine compound preparation containing tilmicosin as described in claims 1 to 3 any one, is characterized in that: described medicinal filling adjuvant is starch.
7. a preparation method that contains the Chinese medicine and western medicine compound preparation of tilmicosin, is characterized in that comprising the following steps:
Get by mass percentage the Radix Astragali 5～30%, Radix Isatidis 5～30% is mixed, more progressively add tilmicosin 2～30%, the medicinal filling auxiliary materials and mixing of taurine 0.5～10%, Folium Isatidis 5～30% and surplus.
8. the preparation method of the Chinese medicine and western medicine compound preparation of tilmicosin as claimed in claim 7, is characterized in that: the described Radix Astragali, Radix Isatidis, Folium Isatidis mix after being all first crushed to superfine powder again.
9. the preparation method of the Chinese medicine and western medicine compound preparation of tilmicosin as claimed in claim 8, is characterized in that: it is more than 300 orders that the described Radix Astragali, Radix Isatidis, Folium Isatidis are crushed to respectively mean diameter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310186990.8A CN103272068B (en) | 2013-05-20 | 2013-05-20 | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310186990.8A CN103272068B (en) | 2013-05-20 | 2013-05-20 | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103272068A CN103272068A (en) | 2013-09-04 |
| CN103272068B true CN103272068B (en) | 2014-07-30 |
Family
ID=49054316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310186990.8A Expired - Fee Related CN103272068B (en) | 2013-05-20 | 2013-05-20 | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103272068B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104083730A (en) * | 2014-07-31 | 2014-10-08 | 刘吉山 | Medicine for preventing and treating mixed infection of pigs, as well as preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103099812A (en) * | 2013-01-21 | 2013-05-15 | 湖北武当动物药业有限责任公司 | Medicine for treating porcine reproductive and respiratory syndrome and preparation method thereof |
-
2013
- 2013-05-20 CN CN201310186990.8A patent/CN103272068B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 2009 年防控猪高热综合征的回顾;万遂如;《养猪SWINE PRODUCTION》;20100131(第1期);第2页 * |
| 万遂如.2009 年防控猪高热综合征的回顾.《养猪SWINE PRODUCTION》.2010,(第1期),33-35. |
| 自制中药制剂"高热灵散"对猪"高热病"治疗试验;邓登义等;《中兽医学杂志》;20100228(第2期);第34页 * |
| 邓登义等.自制中药制剂"高热灵散"对猪"高热病"治疗试验.《中兽医学杂志》.2010,(第2期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103272068A (en) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006916A (en) | Pure traditional Chinese medicine recipe for curing various animal diarrhoeal diseases and preparation method of pure traditional Chinese medicine recipe | |
| CN104000049B (en) | A kind of composition and application thereof preventing and treating lamb dysentery | |
| CN103006892A (en) | Medicine composition for preventing and treating porcine viral diseases, and premix and batch with composition | |
| CN102885201B (en) | Compound Chinese herbal medicine feed additive | |
| CN105851592A (en) | Sow mastitis feed additive with slow-release effect and preparation method | |
| CN102488746A (en) | Compound propolis composition for treating swine infectious atrophic rhinitis and preparation method thereof | |
| CN103272068B (en) | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof | |
| CN101979055A (en) | Medicinal composition for treating fowl pox and preparation method thereof | |
| CN103861007B (en) | A kind of Chinese herbal compound preparation for the treatment of chicken diarrhea | |
| CN108969648B (en) | Pharmaceutical composition and application method thereof | |
| CN106822528A (en) | Treat traditional Chinese medicine oral liquid of sow Postpartum anestrus and preparation method thereof | |
| CN102397533B (en) | Compound propolis composition for treating livestock egg drop syndrome and preparation method thereof | |
| CN101961411B (en) | Medicament for treating aphthosis and preparation method thereof | |
| CN101326968B (en) | Animal feed additives using Zedoary turmeric oil as principal ingredient and preparation thereof | |
| CN104784311B (en) | Composition of medicine for preventing and treating animal aphtha hoof Huang and preparation method thereof | |
| CN105748873A (en) | Veterinary traditional Chinese medicine particle for treating livestock and poultry respiratory tract infection | |
| CN110279771A (en) | A kind of Chinese medicine pre-mixing agent and preparation method thereof for preventing and treating bamboo rat diarrhea | |
| CN103520330A (en) | Veterinary dispersible tablet as well as preparation method and application thereof | |
| CN102846681A (en) | Medicament for treating livestock diarrhea | |
| CN108030906A (en) | A kind of Chinese medicine composition for preventing porcine respiratory disease and feed and preparation method thereof | |
| CN109833305A (en) | Perfume connects the preparation process of antidiarrheal enteric-coated micro-pill | |
| CN107683971A (en) | One boar food and preparation method thereof | |
| CN106361902A (en) | Traditional Chinese medicine composition for preventing and treating livestock diarrhea and preparation method thereof | |
| CN106619921A (en) | Traditional Chinese veterinary medicine composition for treating piglet diarrhea and preparation process of preparation | |
| CN105192321A (en) | Herbal medicine feed additive for prevention and control of duck parasitosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Xiaoyan Inventor after: Fang Binghu Inventor after: Chen Ruiai Inventor after: Yuan Zhaohong Inventor after: Zhan Suizhang Inventor before: Liu Xiaoyan Inventor before: Fang Fanhu Inventor before: Chen Ruiai Inventor before: Yuan Zhaohong Inventor before: Zhan Suizhang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XIAOYAN FANG FANHU CHEN RUIAI YUAN ZHAOHONG ZHAN HUIZHANG TO: LIU XIAOYAN FANG BINGHU CHEN RUIAI YUAN ZHAOHONG ZHAN HUIZHANG |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160623 Address after: 527400 Yunfu City, Xinxing County Province, the new town of North East embankment road, No. 6 Patentee after: GUANGDONG WENS DAHUANONG BIOTECHNOLOGY CO., LTD. Address before: 527400, No. 2, Wen Science Park, east north embankment road, Xinxing County new town, Guangdong, Yunfu, three Patentee before: Guangdong Dahuanong Animal Health Products Co., Ltd. Patentee before: Zhaoqing Dahuanong Biological Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140730 Termination date: 20190520 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |